Development and use of SIV-based Integrase defective lentiviral vector for immunization. - Wikidata - awgldk - TriplyDB

Development and use of SIV-based Integrase defective lentiviral vector for immunization.

Development and use of SIV-based Integrase defective lentiviral vector for immunization.

http://www.wikidata.org/entity/Q37369322

about

Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine.Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice.Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells Optimization of mucosal responses after intramuscular immunization with integrase defective lentiviral vector Immunization delivered by lentiviral vectors for cancer and infectious diseases.Gene therapy for cancer: present status and future perspective Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines.Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques.Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity.Ocular gene delivery using lentiviral vectors.Targeting lentiviral vectors for cancer immunotherapy.Assessment of Integration-defective HIV-1 and EIAV Vectors In Vitro and In Vivo.Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer.Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.Design and Potential of Non-Integrating Lentiviral Vectors.IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells The IS2 Element Improves Transcription Efficiency of Integration-Deficient Lentiviral Vector Episomes

P2860

Q31106756-96231655-C8AE-423C-ADD5-BDDFF791FA4E Q32183405-C79803B3-8A1F-4BC7-8F58-FD7F7ED6ABDF Q33655722-2525E534-DFB8-4EE3-9887-22EF94C26B6F Q33865077-3CF6452D-00AF-4AFB-AEB6-C001F76374F5 Q34085930-6847EE2B-75FD-4309-B685-6FA929E51798 Q34166320-DEC11951-D705-40FF-B063-32E33055E440 Q34539879-2B347269-3595-406E-9826-D810CEAF5199 Q35673900-6A8988B4-B610-46E9-968A-32CB9CC94A2E Q35878409-C8E145E4-2375-41C3-92F2-7C463E1C4BE4 Q36308990-F2D1A825-DC83-416F-A4D1-D930640E2396 Q37499531-2327CEC8-6B78-41B3-8393-6AAB8AF55508 Q37857291-A41F7CDA-AD52-48DB-B169-79F24CF1B644 Q37952564-5744BA78-9571-44E9-9744-FE7AB0CDD53F Q38043924-27DBD5D7-5E2F-4D8B-854B-1895EA993CB1 Q39227747-2A990CE0-5415-4A57-93F0-C8C4D2966577 Q39330979-52CF9E94-8B84-44CA-AD16-37F98E494DA1 Q42533779-22F30492-32A8-49B9-B2B8-CD4A02EE953B Q47113436-864A2701-5FDF-442B-8A96-98D900B61811 Q49829189-27E24ACF-D018-4FDB-B207-E207127A3537 Q51851755-CDDA1442-D822-46E9-ACB1-CBFD9FEB8217 Q57117718-F1744595-B4CF-4077-B599-5BE90221F498 Q58766580-07A01136-E9CE-41DE-B59C-BBDD42802685

P2860

Development and use of SIV-based Integrase defective lentiviral vector for immunization.

http://www.wikidata.org/entity/Q37369322

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Development and use of SIV-based Integrase defective lentiviral vector for immunization.

@en

Development and use of SIV-based Integrase defective lentiviral vector for immunization.

@nl

type

label

Development and use of SIV-based Integrase defective lentiviral vector for immunization.

@en

Development and use of SIV-based Integrase defective lentiviral vector for immunization.

@nl

prefLabel

Development and use of SIV-based Integrase defective lentiviral vector for immunization.

@en

Development and use of SIV-based Integrase defective lentiviral vector for immunization.

@nl

P1433

Q37369322-3436C424-DEEC-463B-8059-9D719D755749

P1476

Q37369322-69A298E7-D877-40BB-A1AE-B9F24DDAB53F

P2093

Q37369322-0758C4C8-F3E3-49BF-A0ED-363BDF575934

Q37369322-7A961466-E9E3-426A-BE95-1521A82945A7

Q37369322-A89C4595-960C-4579-98B7-5B7676114840

P2860

Q37369322-0254C3DA-6BD1-4A16-8C7F-86344AE1B21A

Q37369322-08F7AE69-908C-4013-822D-69BBAD3C12F8

Q37369322-157C70BC-32D8-4D25-81F4-A27A9106901D

Q37369322-15B8BD72-426B-4891-9F71-F80AE9465003

Q37369322-1AF7EE3D-9A72-43EE-946E-28114A2629E5

Q37369322-345855F8-CA8A-4856-8099-252AC4658CD5

Q37369322-4233A9E1-AF93-4080-A6C0-B3FBBA963136

Q37369322-47AE64D6-1F71-4E55-B02F-D9F826930A6A

Q37369322-528DD299-FCAD-4C66-96B7-091B612E94F6

Q37369322-52B1867E-5791-4434-9940-B9E58038FC0F

P304

Q37369322-F38704AB-EF49-4402-9FC7-C7F18A43991C

P31

Q37369322-DB045364-5854-49A6-836A-A3741BE6FCA5

P356

Q37369322-C1D30872-9EEC-48C7-9421-025FB0F4AA89

P407

Q37369322-2E966FD8-5079-45D3-B7E1-7A303DDCA2D4

P433

Q37369322-D8C1D6C6-9A68-4518-974F-12F8B31E6E3E

P478

Q37369322-3B9873EB-E465-4BA2-9529-880EE5C58209

P50

Q37369322-1E4741A1-D308-45A9-BD00-A6FCA7C72F73

Q37369322-36295FB3-F94B-4F53-B3B0-12C7CF0343D7

Q37369322-80D51867-89C1-4EA7-AB05-2958C24F596B

Q37369322-B6E05844-7E0F-48C3-B895-FB927B27FF5E

Q37369322-DC412385-3595-49B7-B63C-0FB1C3FE8B0F

P577

Q37369322-F3C1027E-0C62-401B-BCC9-769941E86D38

P5875

Q37369322-D5D45CF3-23C2-40E3-8AB4-B6C79B55832A

P698

Q37369322-A737A1D3-A584-4BEB-B3EB-049C6A5BE910

P921

Q37369322-5367628F-BE2B-4EC9-A2BE-B1844001B233

P932

Q37369322-864CE32E-7C62-4F87-8EDF-73256CA8E0EA

P356

J.VACCINE.2009.05.070

P1433

P1476

Development and use of SIV-based Integrase defective lentiviral vector for immunization

@en

P2093

Mary E Klotman

http://www.w3.org/2001/XMLSchema#string

Massimo Spada

http://www.w3.org/2001/XMLSchema#string

Pasqualina Leone

http://www.w3.org/2001/XMLSchema#string

P2860

In defense of the cell: TRIM5alpha interception of mammalian retroviruses

Protective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

Effective gene therapy with nonintegrating lentiviral vectors.

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover.

Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds

Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo.

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.

P304

4622-4629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2009.05.070

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Donatella Negri

Zuleika Michelini

P577

2009-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26289708

http://www.w3.org/2001/XMLSchema#string

P698

19523909

http://www.w3.org/2001/XMLSchema#string

P921

P932

2754741

http://www.w3.org/2001/XMLSchema#string